Arthneeti
Latest: Windlas Biotech Ltd Q1 FY27 results →All Q4 FY26 results →
WB

Windlas Biotech Ltd

Q4 FY26Pharmaceuticals & Biotechnology

Windlas Biotech Q4 FY26 earnings call: Revenue & Margins

Q4 FY26 earnings call: what management said on revenue, margins and capex.

Price₹994
Market cap₹2.0K Cr
P/E29.5
Updated23 Aug 2026
Read4 min read

The short version

Windlas Biotech aims for continued growth across its three verticals: CDMO, Trade Generics & Institutional, and Exports. FY '26 performance showed strong growth with revenue at INR 904 crores, 19% YoY increase, and EBITDA margin at ~13.4%.

From Windlas Biotech Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • Windlas Biotech aims for continued growth across its three verticals: CDMO, Trade Generics & Institutional, and Exports.
  • The company targets 18-20% historical growth rates, with potential to reach peak capacity utilization by FY '27.
  • Plant 6 commercialization by H1 FY '27 is expected to support revenue up to INR 1,100 crores, with a 10-15% capacity efficiency improvement possible.
  • Long-term growth in trade generics and institutional verticals driven by geographic expansion, portfolio enhancement, and new institutional accounts.
  • Export vertical expected to grow rapidly, backed by regulatory approvals and product registrations.

2 more points from Windlas Biotech Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Windlas Biotech Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Plant 6 has achieved mechanical completion and is on track for commercialization by H1 FY '27.
  • Planned capex for FY '27 is mainly maintenance capex; no major organic capex expected in FY '27.
  • The company aims to maintain capacity efficiency and unlock 10-15% additional capacity without large new investments.
  • Further capacity expansions will be considered based on utilization; if utilization nears 60%, new capacity planning (possibly in FY '28) may commence.
  • Capital allocation strategy focuses on shorter-term capacity expansions (1.5 to 2.5 years) rather than large 5-year capacity builds.

2 more points from Windlas Biotech Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
1KRM Ayurveda
Rev 1Mar 1
2Accretion Pha.
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Windlas Biotech Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

  • Management mentioned working with a strong pipeline of new ideas and product launches.
  • They focus on filling capacity with alternate products, e.g., replacing codeine syrup lost business.
  • Injectable ramp-up is progressing with regulatory approvals and customer onboarding underway.

2 more points from Windlas Biotech Ltd's call on order book

Create a free account to keep reading this call

Windlas Biotech Ltd — Quarterly revenue & net profit

Revenue Net profit
Dec 2024Q3 FY25
Mar 2025Q4 FY25
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26

Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹238 Cr, net profit ₹16 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Windlas Biotech Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Balaxi Pharmaceuticals Ltd (Q4 FY26)

    Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY

  • Accretion Pharmaceuticals Ltd (Q4 FY26)

    45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks

  • Gujarat Themis Biosyn Ltd (Q4 FY26)

    . Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.

  • Aptus Pharma Ltd (Q4 FY26)

    The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Windlas Biotech Ltd and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Windlas Biotech Ltd Q4 FY26 results?

Windlas Biotech aims for continued growth across its three verticals: CDMO, Trade Generics & Institutional, and Exports. FY '26 performance showed strong growth with revenue at INR 904 crores, 19% YoY increase, and EBITDA margin at ~13.4%.

What is Windlas Biotech Ltd share price analysis?

Windlas Biotech Ltd currently shows a neutral. The stock trades at a P/E of 29.5 with a market cap of ₹1,959 Cr. Investors should review the full earnings analysis for detailed insights.

Is Windlas Biotech Ltd planning capital expenditure?

Plant 6 has achieved mechanical completion and is on track for commercialization by H1 FY '27.

Keep Windlas Biotech Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.